182 related articles for article (PubMed ID: 34756760)
1. Loss of skeletal muscle density during neoadjuvant chemotherapy in older women with advanced stage ovarian cancer is associated with postoperative complications.
van der Zanden V; van Soolingen NJ; Viddeleer AR; Trum JW; Amant F; Mourits MJE; Portielje JEA; Baalbergen A; Souwer ETD; van Munster BC
Eur J Surg Oncol; 2022 Apr; 48(4):896-902. PubMed ID: 34756760
[TBL] [Abstract][Full Text] [Related]
2. Low preoperative skeletal muscle density is predictive for negative postoperative outcomes in older women with ovarian cancer.
van der Zanden V; van Soolingen NJ; Viddeleer AR; Trum JW; Amant F; Mourits MJE; Portielje JEA; van den Bos F; de Kroon CD; Kagie MJ; Oei SA; Baalbergen A; van Haaften-de Jong ALD; Houtsma D; van Munster BC; Souwer ETD
Gynecol Oncol; 2021 Aug; 162(2):360-367. PubMed ID: 34112514
[TBL] [Abstract][Full Text] [Related]
3. Patients triaged to neoadjuvant chemotherapy have higher rates of sarcopenia: An opportunity for prehabilitation.
Fadadu PP; Polen-De CL; McGree ME; Weaver AL; Moynagh MR; Takahashi N; Langstraat CL; Cliby WA; Kumar A
Gynecol Oncol; 2021 Jan; 160(1):40-44. PubMed ID: 33109391
[TBL] [Abstract][Full Text] [Related]
4. Survival and Surgical Approach among Women with Advanced Ovarian Cancer Treated with Neoadjuvant Chemotherapy.
Persenaire C; Pyrzak A; Barber EL
J Minim Invasive Gynecol; 2022 Mar; 29(3):375-384. PubMed ID: 34648931
[TBL] [Abstract][Full Text] [Related]
5. Survival outcome and perioperative complication related to neoadjuvant chemotherapy with carboplatin and paclitaxel for advanced ovarian cancer: A systematic review and meta-analysis.
Machida H; Tokunaga H; Matsuo K; Matsumura N; Kobayashi Y; Tabata T; Kaneuchi M; Nagase S; Mikami M
Eur J Surg Oncol; 2020 May; 46(5):868-875. PubMed ID: 31818526
[TBL] [Abstract][Full Text] [Related]
6. Timing of interval debulking surgery and postoperative chemotherapy after neoadjuvant chemotherapy in advanced epithelial ovarian cancer: a multicenter real-world study.
Liu X; Zhao Y; Jiao X; Yu Y; Li R; Zeng S; Chi J; Ma G; Huo Y; Li M; Peng Z; Liu J; Zhou Q; Zou D; Wang L; Li Q; Wang J; Yao S; Chen Y; Ma D; Hu T; Gao Q
J Ovarian Res; 2023 Jun; 16(1):121. PubMed ID: 37370087
[TBL] [Abstract][Full Text] [Related]
7. Outcomes of advanced epithelial ovarian cancer treated with neoadjuvant chemotherapy.
Maheshwari A; Kumar N; Gupta S; Rekhi B; Shylasree TS; Dusane R; Bajpai J; Ghosh J; Gulia S; Deodhar K; Menon S; Popat P; Sable N; Thakur M; Kerkar R
Indian J Cancer; 2018; 55(1):50-54. PubMed ID: 30147093
[TBL] [Abstract][Full Text] [Related]
8. Characteristics and survival of ovarian cancer patients treated with neoadjuvant chemotherapy but not undergoing interval debulking surgery.
Liu YL; Filippova OT; Zhou Q; Iasonos A; Chi DS; Zivanovic O; Sonoda Y; Gardner GJ; Broach VA; O'Cearbhaill RE; Konner JA; Aghajanian C; Long Roche K; Tew WP
J Gynecol Oncol; 2020 Jan; 31(1):e17. PubMed ID: 31833259
[TBL] [Abstract][Full Text] [Related]
9. Similar Overall Survival Using Neoadjuvant Chemotherapy or Primary Debulking Surgery in Patients Aged Over 75 Years with High-Grade Ovarian Cancer.
Piedimonte S; Kessous R; Laskov I; Abitbol J; Kogan L; Yasmeen A; Salvador S; Lau S; Gotlieb WH
J Obstet Gynaecol Can; 2020 Nov; 42(11):1339-1345. PubMed ID: 32859533
[TBL] [Abstract][Full Text] [Related]
10. When Less Is More: Minimally Invasive Surgery Compared with Laparotomy for Interval Debulking After Neoadjuvant Chemotherapy in Women with Advanced Ovarian Cancer.
Brown J; Drury L; Crane EK; Anderson WE; Tait DL; Higgins RV; Naumann RW
J Minim Invasive Gynecol; 2019; 26(5):902-909. PubMed ID: 30240899
[TBL] [Abstract][Full Text] [Related]
11. Incorporating robotic surgery into the management of ovarian cancer after neoadjuvant chemotherapy.
Abitbol J; Gotlieb W; Zeng Z; Ramanakumar A; Kessous R; Kogan L; Pare-Miron V; Rombaldi M; Salvador S; Kucukyazici B; Brin S; How J; Lau S
Int J Gynecol Cancer; 2019 Nov; 29(9):1341-1347. PubMed ID: 31601648
[TBL] [Abstract][Full Text] [Related]
12. Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer.
Morrison J; Haldar K; Kehoe S; Lawrie TA
Cochrane Database Syst Rev; 2012 Aug; 2012(8):CD005343. PubMed ID: 22895947
[TBL] [Abstract][Full Text] [Related]
13. Study of upfront surgery versus neoadjuvant chemotherapy followed by interval debulking surgery for patients with stage IIIC and IV ovarian cancer, SGOG SUNNY (SOC-2) trial concept.
Jiang R; Zhu J; Kim JW; Liu J; Kato K; Kim HS; Zhang Y; Zhang P; Zhu T; Aoki D; Yu A; Chen X; Wang X; Zhu D; Zhang W; Jia H; Shi T; Gao W; Yin S; Feng Y; Xiang L; Okamoto A; Zang R
J Gynecol Oncol; 2020 Sep; 31(5):e86. PubMed ID: 32808504
[TBL] [Abstract][Full Text] [Related]
14. Impact of prehabilitation during neoadjuvant chemotherapy and interval cytoreductive surgery on ovarian cancer patients: a pilot study.
Miralpeix E; Sole-Sedeno JM; Rodriguez-Cosmen C; Taus A; Muns MD; Fabregó B; Mancebo G
World J Surg Oncol; 2022 Feb; 20(1):46. PubMed ID: 35197061
[TBL] [Abstract][Full Text] [Related]
15. Upfront cytoreductive surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer in Indian patients.
Ray MD; Deo SSV; Kumar L; Gaur MK
Future Oncol; 2021 Sep; 17(27):3607-3614. PubMed ID: 34263662
[TBL] [Abstract][Full Text] [Related]
16. Factors associated with delivery of neoadjuvant chemotherapy in women with advanced stage ovarian cancer.
Hinchcliff E; Melamed A; Bregar A; Diver E; Clemmer J; Del Carmen M; Schorge JO; Alejandro Rauh-Hain J
Gynecol Oncol; 2018 Jan; 148(1):168-173. PubMed ID: 29128105
[TBL] [Abstract][Full Text] [Related]
17. [Analysis of factors related to the prognostic benefit of neoadjuvant chemotherapy followed by interval debulking surgery in patients with advanced ovarian cancer].
Wang DF; Zhang GN; Peng CR; Shi Y; Shi XW
Zhonghua Fu Chan Ke Za Zhi; 2021 Jun; 56(6):385-392. PubMed ID: 34154313
[No Abstract] [Full Text] [Related]
18. The importance of the Peritoneal Cancer Index (PCI) to predict surgical outcome after neoadjuvant chemotherapy in advanced ovarian cancer.
Rawert FL; Luengas-Würzinger V; Claßen-Gräfin von Spee S; Baransi S; Schuler E; Carrizo K; Dizdar A; Mallmann P; Lampe B
Arch Gynecol Obstet; 2022 Nov; 306(5):1665-1672. PubMed ID: 35357582
[TBL] [Abstract][Full Text] [Related]
19. Critical Analysis of Stage IV Epithelial Ovarian Cancer Patients after Treatment with Neoadjuvant Chemotherapy followed by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC).
Munoz-Zuluaga CA; Sardi A; Sittig M; Gushchin V; King MC; Nieroda C; Lopez-Ramirez F; Diaz-Montes TP
Int J Surg Oncol; 2020; 2020():1467403. PubMed ID: 33381312
[TBL] [Abstract][Full Text] [Related]
20. Trends in the use of neoadjuvant chemotherapy for low-grade serous ovarian cancer in the United States.
Silberman JN; Bercow AS; Gockley AA; Eisenhauer EL; Sisodia R; Randall T; Del Carmen MG; Goodman A; Castro CM; Melamed A; Bregar AJ
Gynecol Oncol; 2023 Aug; 175():60-65. PubMed ID: 37327540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
